GLSI-100

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years for a total of 11 injections over 3 years. Contact Information: Greenwich LifeSciences, Inc. Stafford, TX Email: Flamingo-01@greenwichlifesciences.com Website: greenwichlifesciences.com

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years. The trial objectives are to: 1) Determine if GP2 therapy increases IBCFS, 2) Assess the safety profile of GP2, and 3) Monitor immunologic responses to treatment and assess relationship to efficacy and safety. The study has been initiated in the US with plans to open in Europe.

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years for a total of 11 injections over 3 years. The study is also expected to be opened in Spain, Germany, and France. Clinical trial information: NCT05232916.

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years. The trial objectives are to: 1) Determine if GP2 therapy increases IBCFS, 2) Assess the safety profile of GP2, and 3) Monitor immunologic responses to treatment and assess relationship to efficacy and safety. The study has been initiated in the US with plans to open in Europe.

Funding: This trial is supported by Greenwich LifeSciences. Up to 100 non-HLA-A*02 subjects will be enrolled in an open-label arm.Eligibility Criteria: The patient population is defined by these key eligibility criteria: 1) HER2/neu positive and HLA-A*02; 2) Residual disease or High risk pCR (Stage III at presentation) post neo-adjuvant therapy; 3) Exclude Stage IV; and 4) Completed at least 90% of planned trastuzumab-based therapy.Trial Objectives: 1) To determine if GP2 therapy increases IBCFS; 2) To assess the safety profile of GP2; and 3) To monitor immunologic responses to treatment and assess relationship to efficacy and safety.Study Status: The study has been initiated at a number of sites in the US. The study is also expected to be opened in Spain, Germany, and France.

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years for a total of 11 injections over 3 years. To assess the safety profile of GP2 3. To monitor immunologic responses to treatment and assess relationship to efficacy and safety

No abstract available

After 1 year of trastuzumab-based therapy, 6 intradermal injections of GLSI-100 or placebo will be administered over the first 6 months and 5 subsequent boosters will be administered over the next 2.5 years for a total of 11 injections over 3 years. T-cells that were present at baseline potentially represent the existing immune state and may contain some GP2 specific T- cells, which will be confirmed with future singe cell sequencing experiments that identify T-cells specific to GP2 and other antigens. T-cells that expanded after treatment with GLSI-100 are potentially GP2 specific T-cells and may be mechanistically relevant. These findings support further study of the use of TCR sequencing to assess immune response to GLSI-100 vaccination.]

P3, N=598, Recruiting, Greenwich LifeSciences, Inc. | Not yet recruiting --> Recruiting

Background: Delayed type hypersensitivity (DTH) skin tests to GP2 were conducted in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial investigating GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2. Baseline GP2 immune response as measured by the delayed-type hypersensitivity test may be an independent prognostic factor for recurrence. Knowledge of this GP2 immune response may identify a patient with increased risk of rapid recurrence.

Background: Injection site reactions (ISR) of booster injections in the randomized, active-controlled, single-blinded, multicenter Phase IIb trial of GLSI-100 (GP2+GM-CSF) administered in the adjuvant setting to node-positive and high-risk node-negative breast cancer patients with tumors expressing HER2 have been analyzed. Administering GLSI-100 boosters at 6 month intervals to patients produced a consistent nadir ISR approximately 20 mm lower than the maximum PIS ISR of 92.1 mm which is still larger than the maximum ISR in GM-CSF only patients of 60.5 mm. A patient’s immune response a month after booster dosing would theoretically be the peak ISR, which will be measured in future trials by measuring T-cell response and DTH one month after booster injections, further helping to evaluate booster strategies to sustain peak immunity over longer periods of time.

The participant duration of the trial will be 3 years treatment plus 1 additional year follow-up for a total of 4 years following the first year of treatment with trastuzumab-based therapy. Patients will be stratified based on residual disease status at surgery, hormone receptor status, prior pertuzumab therapy and region...Target enrollment is 598 subjects.Contact information: Snehal Patel Greenwich LifeSciences, Inc. Stafford, TX Email: snehal.patel@greenwichlifesciences.com Website: greenwichlifesciences.com

The authors did not submit an updated abstract. The original abstract should be considered final.

The authors did not submit an updated abstract. The original abstract should be considered final.

P3, N=598, Not yet recruiting, Greenwich LifeSciences, Inc. | Trial completion date: Dec 2027 --> Dec 2026 | Trial primary completion date: Dec 2027 --> Dec 2026

P3, N=598, Not yet recruiting, Greenwich LifeSciences, Inc.

Background : GP2 is a biologic nine amino acid peptide of the HER2/ neu protein delivered in combination with an FDA-approved immunoadjuvant Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF, Sargramostim, Leukine) that stimulates an immune response targeting HER2/neu expressing cancers. This sample size provides 80% power if the annual rate of events in placebo-treated patients is 2.4% or greater. Eligibility Criteria : The patient population is defined by these key eligibility criteria: HER2/neu positive and HLA-A*02 Residual disease or High risk pCR (Stage III at presentation) post appropriate neo-adjuvant therapy Exclude Stage IV Completed at least 75% of planned trastuzumab-based therapy Trial Objectives : To determine if GP2 therapy increases invasive disease-free survival (IDFS) To assess the safety profile of GP2 To monitor immunologic responses to treatment and assess relationship to efficacy and safety Contact information : Website: greenwichlifesciences.com Funding : This trial is supported by Greenwich LifeSciences.